Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT06612879
- Locations
- 🇺🇸
Fortrea Madison WI, CRU, Madison, Wisconsin, United States
A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 69
- Registration Number
- NCT06574828
- Locations
- 🇺🇸
Austin Clinic PPD, Austin, Texas, United States
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Device: ThecaFlex DRx System
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Biogen Idec Research Limited
- Target Recruit Count
- 26
- Registration Number
- 2024-514239-21-00
- Locations
- 🇫🇷
Centre Hospitalier Regional De Marseille, Marseille, France
🇫🇷Assistance Publique Hopitaux De Paris, Garches, France
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 5
- Registration Number
- NCT06454721
- Locations
- 🇺🇸
UC Davis, Sacramento, California, United States
A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT06311786
- Locations
- 🇺🇸
PPD Clinical Research Unit, Austin, Texas, United States
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 18
- Registration Number
- NCT06264440
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 300
- Registration Number
- NCT06262477
- Locations
- 🇬🇧
Fortrea Clinical Research Unit Inc., Leeds, West Yorkshire, United Kingdom
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 474
- Registration Number
- NCT06127095
- Locations
- 🇺🇸
Biogen, Cambridge, Massachusetts, United States
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- HI-Bio, A Biogen Company
- Target Recruit Count
- 20
- Registration Number
- NCT06064929
- Locations
- 🇺🇸
Accurate Clinical Research - Katy, Katy, Texas, United States
🇺🇸Centricity Research - Phoenix, Mesa, Arizona, United States
🇺🇸University of California, San Diego (UCSD), La Jolla, California, United States
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 35
- Registration Number
- NCT06054893
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States